CGB 0.00% 2.1¢ cann global limited

medical cannabis pill, page-7

  1. 837 Posts.
    lightbulb Created with Sketch. 42
    How could anyone possibly know even a ball park price? As a pharmacist with long experience I would say that a PBS listing is a long way off. Governments move extremely slowly. Secondly the price will tend to be higher than opiate derivatives, because R&D costs today are way higher than in decades past, when opiates were brought to the market.
    Also a more compelling therapeutic effect and side effect profile. Also supply and demand natural market forces; demand will be strong assuming the pain relief will be highly significant. Opiates lose their analgesic effect rapidly with continuous use, and dependency ensues quite soon after which is the really big issue.
    However severe chronic pain is so debilitating that price won't be that important.
 
watchlist Created with Sketch. Add CGB (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.